News
JAGX
0.3700
-1.31%
-0.0049
Jaguar Health's Italian firm applies for orphan drug designation for crofelemer to EMA
Jaguar Health (NASDAQ:JAGX) said on Wednesday its Italian firm Napo Therapeutics had submitted an Orphan Drug Designation application for crofelemer to treat a rare congenital diarrhea disorder condition called microvillus inclusion disease to
Seekingalpha · 1d ago
Jaguar Health Announces Napo Therapeutics' Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition
The submission is the first step of the process; the review by the EMA's Committee for Orphan Medicinal Products (COMP) will start after the validation of the submission."CDDs are a group of inherited chronic enteropathies characterized by heterogeneous et...
ACCESSWIRE · 2d ago
Jaguar Health Seeks EU's Orphan Drug Designation for Crofelemer in Congenital Diarrheal Disorder
MT Newswires · 2d ago
Jaguar Health Highlights Presentation Of Investigator-Initiated Evaluation Of Crofelemer For Severe Congenital Diarrheal Disorder At Digestive Disease Week
Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea SAN
Benzinga · 3d ago
Jaguar Health Announces Presentation of an Investigator-initiated Evaluation of Crofelemer for a Severe Congenital Diarrheal Disorder at 2022 Digestive Disease Week
Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrheaSAN FRANCISCO, CA / ACCESSWIRE / May 24, 2022 ...
ACCESSWIRE · 3d ago
Jaguar Health Announces Launch Of The First U.S. Canine Cancer Registry And Canine Cancer Care Index
Jaguar Health, Inc. (NASDAQ:JAGX) today announced the launch of Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange), a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index to
Benzinga · 4d ago
Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index
" (Canine Health And ReGistry Exchange) Based on Nationwide Gallup Poll of Pet Owners and Initial Assessment of More Than 35,000 Canine Medical RecordsInitial Data from Gallup Poll of More Than 3,500 Dog Owners Suggest Nearly Five-Fold Greater Incidence of...
ACCESSWIRE · 4d ago
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!
Click Here To RSVP for This In-Person, Outdoor EventHuman and Doggy Swag Will Be Available*, and the Event Will Feature Presentations by Well-Known Veterinary Cancer Specialists, Including Dr. Sue Cancer Vet, and Performances by Broadway StarsThis Is a Spe...
ACCESSWIRE · 05/17 12:55
30 Stocks Moving in Monday's Pre-Market Session
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday.
Benzinga · 05/16 10:57
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 89.7% to $0.1480 in pre-market trading after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
Benzinga · 05/12 10:17
TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health
SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that TAG Investment Bankers Ltd.
ACCESSWIRE · 05/11 18:30
Jaguar Health Announces Launch Of Mytesi Telehealth Program
aguar Health, Inc. (NASDAQ:JAGX) today announced that the company's telehealth program went live on May 6, 2022 for Mytesi (crofelemer), Jaguar's FDA-approved antidiarrheal prescription drug indicated
Benzinga · 05/11 12:34
BRIEF-Jaguar Health Inc Qtrly Loss Per Share $0.40
reuters.com · 05/10 12:17
Jaguar Health Q1 EPS $(0.40) Down From $(0.27) YoY, Sales $2.63M Beat $1.62M Estimate
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(0.40) per share. This is a 48.15 percent decrease over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $2.63
Benzinga · 05/10 12:09
Jaguar Health GAAP EPS of -$0.40 misses by $0.23, revenue of $2.62M beats by $1M
Jaguar Health press release (NASDAQ:JAGX): Q1 GAAP EPS of -$0.40 misses by $0.23. Non-GAAP EBITDA for the first quarter of 2022 and the first quarter of 2021 was a net
Seekingalpha · 05/10 12:03
Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials
Eastern regarding first quarter 2022 financials and company updates; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / May 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided company updates and reported...
ACCESSWIRE · 05/10 12:00
-- Earnings Flash (JAGX) JAGUAR HEALTH Posts Q1 Revenue $2.6M
MT Newswires · 05/10 08:16
-- Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Loss $-0.40
MT Newswires · 05/10 08:10
Jaguar Health Q1 2022 Earnings Preview
Jaguar Health (NASDAQ:JAGX) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.18 (-80.0% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 05/09 16:45
Notable earnings before Tuesday's open
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS,
Seekingalpha · 05/09 15:06
More
Webull provides a variety of real-time JAGX stock news. You can receive the latest news about Jaguar Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About JAGX
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. The Company's other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.